Global Initiative for Asthma, Global Strategy for Asthma management and Prevention 2019 [Internet]. [cited 1 dec 2019]. Disponible sur:, 2019 http://www.ginasthma.org/.
ASTHMA FACTS – CDC's National Asthma Control Program Grantees, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA, 2013.
Chung, K.F., Wenzel, S.E., Brozek, J.L., Bush, A., Castro, M., Sterk, P.J., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 43:2 (2014), 343–373.
Licari, A., Marseglia, G., Castagnoli, R., Marseglia, A., Ciprandi, G., The discovery and development of omalizumab for the treatment of asthma. Expert Opin. Drug Discov. 10:9 (2015), 1033–1042.
Storms, W., Allergens in the pathogenesis of asthma: potential role of anti-immunoglobulin E therapy. Am. J. Respir. Med. 1:5 (Oct 2002), 361–368.
D'Amato, G., Stanziola, A., Sanduzzi, A., Liccardi, G., Salzillo, A., Vitale, C., et al. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review. [cited 1 dec 2019];9(1). Available on: Multidiscip. Respir. Med. [Internet], 2014 https://mrmjournal.biomedcentral.com/articles/10.1186/2049-6958-9-23.
Holgate, S.T., Chuchalin, A.G., Hébert, J., Lötvall, J., Persson, G.B., Chung, K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allerg. J. Br. Soc. Allerg. Clin. Immunol. 34:4 (Apr 2004), 632–638.
Hanania, N.A., Alpan, O., Hamilos, D.L., Condemi, J.J., Reyes-Rivera, I., Zhu, J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 154:9 (2011), 573–582.
Corren, J., Casale, T.B., Lanier, B., Buhl, R., Holgate, S., Jimenez, P., Safety and tolerability of omalizumab. Clin. Exp. Allerg. 39:6 (2009), 788–797.
Barnes, N., Menzies-Gow, A., Mansur, A.H., Spencer, D., Percival, F., Radwan, A., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J. Asthma 50:5 (2013), 529–536.
Brusselle, G., Michils, A., Louis, R., Dupont, L., Van, B., de, Maele, Delobbe, A., et al. “Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir. Med. 103:11 (2009), 1633–1642.
Rubin, A.S., Souza-Machado, A., Andradre-Lima, M., Ferreira, F., Honda, A., Matozo, T.M., et al. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J. Asthma 49:3 (2012), 288–293.
Korn, S., Thielen, A., Seyfried, S., Taube, C., Kornmann, O., Buhl, R., Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir. Med. 103:11 (2009), 1725–1731.
Molimard, M., Buhl, R., Niven, R., Le Gros, V., Thielen, A., Thirlwell, J., et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir. Med. 104:9 (2010), 1381–1385.
Braunstahl, G.-J., Chen, C.-W., Maykut, R., Georgiou, P., Peachey, G., Bruce, J., The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir. Med. 107:8 (2013), 1141–1151.
Humbert, M., Beasley, R., Ayres, J., Slavin, R., Hébert, J., Bousquet, J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:3 (2005), 309–316.
Cazzola, M., Camiciottoli, G., Bonavia, M., Gulotta, C., Ravazzi, A., Alessandrini, A., et al. Italian real-life experience of omalizumab. Respir. Med. 104:10 (2010), 1410–1416.
Bhutani, M., Yang, W.H., Hébert, J., de Takacsy, F., Stril, J.-L., The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: the ASTERIX Observational study. Fehrenbach H, éditeur. PLoS One, 12(8), 2017, e0183869.
Haldar, P., Brightling, C.E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360:10 (2009), 973–984.
Cruse, G., Activation of human lung mast cells by monomeric immunoglobulin E. Eur. Respir. J. 25:5 (2005), 858–863.
Djukanović, R., Wilson, S.J., Kraft, M., Jarjour, N.N., Steel, M., Chung, K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med. 170:6 (2004), 583–593.
Acer, E., Kaya, H., Erdogan, Yüksel Çanakçı, N., Saracoglu, Z.N., The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutaneous Ocular Toxicol. 38:1 (2019), 5–8.
Çildağ, S., Şentürk, T., The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. Adv. Dermatol. Allergol. 35:5 (2018), 516–519.
Yalcin, A.D., Celik, B., Yalcin, A.N., Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol. Immunotoxicol. 38:3 (2016), 253–256.
Hanania, N.A., Wenzel, S., Rosén, K., Hsieh, H.-J., Mosesova, S., Choy, D.F., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 187:8 (Apr 2013), 804–811.
Humbert, M., Taillé, C., Mala, L., Le Gros, V., Just, J., Molimard, M., Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. Eur. Respir. J., 51(5), 2018, 1702523.
Kallieri, M., Papaioannou, A.I., Papathanasiou, E., Ntontsi, P., Papiris, S., Loukides, S., Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgrad. Med. 129:6 (2017), 598–604.
Demarche, S.F., Schleich, F.N., Henket, M.A., Paulus, V.A., Van Hees, T.J., Louis, R.E., Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre. BMJ Open, 7(11), 2017, e018186.
Verhamme, K.M.C., Lucet, C., Van Meerhaeghe, A., Brusselle, G.G.O., Lambert, M.-L., Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium. ERJ Open Res. 5:4 (2019), 00253–2018.